Developing Safety Criteria for Introducing New Agents into Neoadjuvant Trials
暂无分享,去创建一个
D. Berry | L. Esserman | O. Olopade | L. Pusztai | Minetta C. Liu | D. Yee | L. Rubinstein | C. Benz | B. Leyland-Jones | H. Rugo | A. DeMichele | K. Albain | John W. Park | B. Parker | P. Munster | D. Tripathy | P. Haluska | J. Perlmutter | J. Zujewski | M. Buxton | A. Chien | J. Lyandres | S. Hunsberger | J. Tomaszewski | A. Jo Chien | Gary Kelloff
[1] Nola Hylton,et al. Pathologic complete response predicts recurrence-free survival more effectively by cancer subset: results from the I-SPY 1 TRIAL--CALGB 150007/150012, ACRIN 6657. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] Richard Pazdur,et al. Pathological complete response and accelerated drug approval in early breast cancer. , 2012, The New England journal of medicine.
[3] P. Fasching,et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] D. Berry. Adaptive clinical trials in oncology , 2012, Nature Reviews Clinical Oncology.
[5] Neal J Meropol,et al. The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] D. Gary Gilliland,et al. Drug development and clinical trials—the path to an approved cancer drug , 2012, Nature Reviews Clinical Oncology.
[7] Janet Woodcock,et al. Accelerating identification and regulatory approval of investigational cancer drugs. , 2011, JAMA.
[8] Edward S. Kim,et al. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC) , 2011, Investigational New Drugs.
[9] D. Berry. Adaptive clinical trials: the promise and the caution. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] S. Martino,et al. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial , 2009, The Lancet.
[11] L. Esserman,et al. I‐SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy , 2009, Clinical pharmacology and therapeutics.
[12] Jingqin Luo,et al. Outcome Prediction for Estrogen Receptor–Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor Characteristics , 2008, Journal of the National Cancer Institute.
[13] J. Milanowski,et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] Joseph A DiMasi,et al. Economics of new oncology drug development. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Norman Wolmark,et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Xin Li,et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] Roy S Herbst,et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 2. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. Giaccone,et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial--INTACT 1. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] H. Muss,et al. Patient preferences for treatment of metastatic breast cancer: a study of women with early-stage breast cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] C. Osborne,et al. Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] W. Fleming,et al. ANTAGONISM OF MONOAMINE OXIDASE INHIBITORS AGAINST NOREPINEPHRINE ACETYLCHOLINE AND POTASSIUM IN THE ISOLATED NICTITATING MEMBRANE OF THE CAT. , 1965, The Journal of pharmacology and experimental therapeutics.